论文部分内容阅读
目的:通过n 68Ga-成纤维细胞激活蛋白抑制剂(FAPI)-04 PET显像探索胰腺癌对FAPI的摄取，为胰腺癌成纤维细胞激活蛋白(FAP)靶向显像提供依据。n 方法:构建胰腺癌-人源肿瘤异种移植(PDX)荷瘤裸鼠模型(n n＝8)，分别行n 68Ga-FAPI-04和n 18F-脱氧葡萄糖(FDG) microPET/CT显像(每组各4只)，采用两独立样本n t检验比较2种显像剂在肿瘤中的每克组织百分注射剂量率(%ID/g)。对5例胰腺癌患者[男4例、女1例，年龄46~74(63.0±11.9)岁]分别行n 68Ga-FAPI-04与n 18F-FDG PET/CT显像，采用配对n t检验比较2种显像剂在胰腺癌原发灶的最大标准摄取值(SUVn max)及肝转移灶与正常肝组织的SUVn max比值。n 结果:MicroPET/CT显像示，n 68Ga-FAPI-04在胰腺癌-PDX荷瘤裸鼠肿瘤组织中各个时间点均有显像，注射后60 min，n 68Ga-FAPI-04在胰腺癌-PDX荷瘤裸鼠肿瘤组织中的摄取显著高于n 18F-FDG [(6.58±0.44)和(4.29±0.13) %ID/g；n t＝4.152，n P＝0.008 9]。5例胰腺癌患者n 68Ga-FAPI-04在胰腺癌原发灶的SUVn max显著高于n 18F-FDG(16.82±3.08和5.14±2.20；n t＝6.893，n P＝0.000 1); n 68Ga-FAPI-04的胰腺癌肝转移灶与正常肝组织的SUVn max比值也显著高于n 18F-FDG(4.57±1.47和1.30±0.16；n t＝3.803，n P＝0.019 1)。n 结论:胰腺癌可高度摄取n 68Ga-FAPI-04，提示FAP有望作为胰腺癌良好的分子靶点，用于胰腺癌PET/CT显像。n “,”Objective:To exploring the uptake of fibroblast activation protein (FAP) inhibitor (FAPI) in pancreatic cancer through n 68Ga-FAPI-04 PET/CT imaging, and provide a basis for the FAP-targeted imaging of pancreatic cancer.n Methods:Pancreatic cancer-patient-derived tumor xenograft (PDX) mouse models (n n=8) were developed, then n 68Ga-FAPI-04 and n 18F-FDG microPET/CT imaging were performed (4 in each group). The differences of percentage activity of injection dose per gram of tissue (%ID/g) of n 68Ga-FAPI-04 and n 18F-FDG were analyzed by independent-sample n t test. n 68Ga-FAPI-04 and n 18F-FDG PET/CT imaging were performed in 5 patients (4 males, 1 female, age: 46-74 (63.0±11.9) years) with pancreatic cancer, and the maximum standardized uptake value (SUVn max) of n 68Ga-FAPI-04 and n 18F-FDG in primary pancreatic cancer and the SUVn max ratio of liver metastases to liver tissue were compared by paired n t test.n Results:MicroPET/CT imaging showed that n 68Ga-FAPI-04 was obviously uptaken at all time points in the tumor of PDX mice. The uptake of n 68Ga-FAPI-04 in PDX mice 60 min after injection was significantly higher than that of n 18F-FDG ((6.58±0.44) and (4.29±0.13) %ID/g; n t=4.152, n P=0.008 9). PET/CT showed that the SUVn max of n 68Ga-FAPI-04 in pancreatic cancer was significantly higher than that of n 18F-FDG (16.82±3.08 and 5.14±2.20; n t=6.893, n P=0.000 1) and the SUVn max ratio of liver metastases to liver tissue of n 68Ga-FAPI-04 was also significantly higher than that of n 18F-FDG (4.57±1.47 and 1.30±0.16; n t=3.803, n P=0.019 1).n Conclusion:68Ga-FAPI-04 can be highly uptaken in pancreatic cancer, suggesting that FAP can be a potential target for PET/CT imaging of pancreatic cancer.n